2017 & Beyond Next Phase Innovative Growth Drivers. Analyst Event July 27, 2015
|
|
- Melvyn Long
- 5 years ago
- Views:
Transcription
1 2017 & Beyond Next Phase Innovative Growth Drivers Analyst Event July 27,
2 Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking statements regarding future events or the future financial performance of Cepheid. We wish to caution you that such statements are just projections and that actual events or results may differ materially. We refer you to the documents that we have filed from time to time with the SEC, specifically our last filed Forms 10-K and 10-Q. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in these projections and forward looking statements. 2
3 John Bishop Chairman and CEO Joined Cepheid as CEO in 2002, Chairman since 2013 Formerly Vysis (acquired by Abbott), MicroProbe, GenProbe, and American Hospital Supply Chairman of AdvaMed Dx Director of Veracyte, Former Director of Conceptus (acquired by Bayer) 3
4 Cepheid s Achievements To Date 4 32% CAGR 23 Xpert Tests 182 Countries 8,903 GeneXpert Systems 43,000 Modules 13,000,000+ Anthrax Tests (Cumulative) 15,000,000+ Xpert Tests (Annually)
5 Commercial Clinical Reagent Revenue Growth $400 $350 $300 $250 32% CAGR ( ) $200 $150 $100 $50 $- Millions shown for illustrative purposes only chart is not reflective of company expectations.
6 Solid Record on Test Menu Expansion & More to Come US HAI Sexual Health Virology Oncology International
7 A Rate of System Placement Unmatched in the Industry HBDC International North America
8 More Systems Installed Than Any Other MDx Manufacturer 25% System Installed Base as % of Total Instruments (Different Colors Represent Different Systems Offered by Same Manufacturer) 20% 15% 10% 5% 8 0% Other Abbott Siemens Qiagen Meridian biomerieux LDT Becton Bioscience Dickinson Source: Market Diagnostics International, IVD Insights, Molecular Infectious Disease , March US Only. Excludes Unspecified or Incomplete Respondents. Hologic Roche Cepheid
9 Ongoing System Innovation : Honeycomb Module 2011: Infinity : Infinity : GeneXpert System 2000: SmartCycler 9
10 Focused Strategic Initiatives Driving Growth Menu Expansion Test Menu Additions & Extensions Hardware Innovations Software & Electronic Data Transmission Targeted ex-us: end 2015, end
11 Focused Strategic Initiatives Driving Growth Menu Expansion Test Menu Additions & Extensions Hardware Innovations Software & Electronic Data Transmission Market Segment Expansion Direct Reach into Smaller Hospitals Reference Labs $10 $9 $8 $7 $6 $5 $4 $3 $2 $1 Global MDx Market POC Market Reference Lab Market Hospital Market CLIA-Waived, POC $ Source: Cepheid Estimates 11
12 Focused Strategic Initiatives Driving Growth Menu Expansion Test Menu Additions & Extensions Hardware Innovations Software & Electronic Data Transmission Cepheid Industry International North America Market Segment Expansion Direct Reach into Smaller Hospitals Reference Labs CLIA-Waived, POC International Expansion Extending Direct Footprint Entering New Markets (China, Japan, India, Brazil) Progressing through Regulatory 12
13 Today We re Addressing Just Two of Our Drivers Menu Expansion Test Menu Additions & Extensions: Oncology Hardware Innovations Software & Electronic Data Transmission Market Segment Expansion Direct Reach into Smaller Hospitals Reference Labs CLIA-Waived, POC International Expansion Extending Direct Footprint Entering New Markets (China, Japan, India, Brazil) Progressing through Regulatory 13
14 Introduction Oncology Target Business Model Updated 5 Year Menu Point-of-Care 14
15 Introduction Oncology Target Business Model Updated 5 Year Menu Point-of-Care 15
16 Michael Bates, MD Vice President, Oncology Research & Development Joined Cepheid in 2011 Formerly at Monogram, ViroLogic, Roche 20 yrs research in oncology, cardiology & ID UCSF, Dana Farber Cancer Institute/Harvard, Duke, Fred Hutchinson Cancer Research Center 16
17 Cancer Today 1 in 7 Global Deaths Caused by Cancer (more than TB, HIV & Malaria combined) 1 in 4 US Deaths Caused by Cancer 1 in 3 Lifetime Chance of Developing Cancer (Female, US) 1 in 2 Lifetime Chance of Developing Cancer (Male, US) 17
18 A Growing Problem as Population Ages, Urbanizes Diagnosed: Living with Cancer: Cancer Deaths: 14 million (2012) 33 million 8 million 18
19 A Growing Problem as Population Ages, Urbanizes Diagnosed: Living with Cancer: Cancer Deaths: 14 million (2012) 33 million 8 million 22 million (2030) 54 million* 13 million 19 Source: American Cancer Society Global Cancer Facts & Figures 2 nd Edition (2011) and 3 rd Edition (2015), *Cepheid Estimates
20 There is Some Good News 3 Routine Monitoring 2 Targeted Therapies 1 Earlier Diagnosis 20
21 Cancer Tomorrow 5-Year Survival Rate 49% 55% 68% Cancer as a Manageable Chronic Condition like HIV Future Source: Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. 21
22 Oncology Diagnostics Today Improving Clinical Utility Slow Expensive Highly Complex Not Standardized Cepheid s Vision Faster and Earlier Diagnosis Cost Effective Testing Testing Closer to the Patient More Frequent Monitoring Improved Patient Outcomes 22
23 Oncology Opportunity Companion Diagnostic (Incidence Rate) Monitoring & Therapeutic Guidance (Prevalence Rate) Early Detection (Asymptomatic At Risk) 23 Source: Cepheid estimates based on internal analysis of breast and prostate cancers.
24 Extending GeneXpert Technology Capabilities RNA Expression DNA Mutations/Genomic Alterations (gene amplification, deletion, etc) DNA Methylation Changes 24
25 Foundational Technologies for Cepheid Oncology Paraffin Embedded Tissue Honeycomb ctdna 25
26 ctdna for Broad Applications in Solid Tumor Oncology Multiple studies* suggest feasibility of liquid biopsy Cepheid viral load assays are highly sensitive for nucleic acids in plasma/serum, similar to ctdna Optimizing to deliver ctdna-based Xpert tests * Bettegowda et al., Sci Transl Med, 2014 Misale et al., Sci Transl Med, 2014 Dawson, et al., NEJM, 2013 Diaz et al., JCO,
27 Foundational Technologies for Cepheid Oncology Paraffin Embedded Tissue Honeycomb ctdna Methylation 27
28 What is DNA Methylation and Why Does it Matter? DNA methylation changes occur very early in cancer development DNA promoter hypermethylation turns off tumor suppressors Because DNA hypermethylation occurs early in cancer, even before gene mutations, it provides an opportunity for early detection Normal Cancer Oncogenes Tumor Suppression 28
29 Methylation Until Now was Largely a Research Tool Correlation between cancer and DNA methylation well known Johns Hopkins investigators pioneered these discoveries in the 1980s-90s Detection methodology restricted to the research arena Slow, cumbersome Difficult to control Requires harsh chemicals 29
30 medna PCR: Same Xpert Ease-of-Use Integrated Platform and Test Add Serum to Lysis Reagent vial Vortex to mix Add Sample Insert Cartridge and Start Test Total Test Time <2 Hours 30
31 Impressive Early Xpert DNA methylation Results Strong agreement in blinded serum specimens (breast cancer) between GX prototype & John Hopkins assay Unpublished data (Fackler, Sukumar, Lai, Kohlway) Superior sensitivity Unpublished data (Kohlway, Lai) Data generated using ctdna 31 Source: Blinded comparison of GX-MSP and cmethdna Cumulative Methylation Index (CMI). Shared with permission.
32 Collaboration with Johns Hopkins on Methylation Xpert Breast CA Monitor Xpert Pancreatic CA Early Detection Xpert Prostate CA Early Detection Xpert Prostate CA Risk Stratification 32
33 Foundational Technologies for Cepheid Oncology Paraffin Embedded Tissue Honeycomb ctdna Methylation 33
34 Providing Broad Xpert Capability with Prototype Tests Analyte Type RNA Expression DNA Mutations Methylation Serum/Plasma, Urine, ctdna Tissue (FFPE) 34
35 Providing Broad Xpert Capability with Prototype Tests Analyte Type RNA Expression DNA Mutations Methylation Tissue (FFPE) Breast Stratifier Breast Signature Serum/Plasma, Urine, ctdna Bladder BCR-ABL Breast Monitor 35
36 Providing Broad Xpert Capability with Prototype Tests Analyte Type RNA Expression DNA Mutations Methylation Tissue (FFPE) Breast Stratifier Breast Signature ESR1 (Breast) EGFR (Lung) KRAS (Pancreatic/Colorectal) Prostate Risk Signature Serum/Plasma, Urine, ctdna Bladder BCR-ABL CLL ESR1 (Breast) EGFR (Lung) KRAS (Pancreatic/Colorectal) Breast Monitor Pancreatic Early Detection Prostate Early Detection 36
37 37 Can Cepheid Compete in Oncology?
38 Oncology Test Development In Practice Biomarker Discovery Test Prototype Test Optimization Training Dataset (Alpha-like) Confirmatory Dataset (Beta-like) Validation Dataset (Clinical Trial) 38
39 Oncology Test Development In Practice: Breast CA Signature Biomarker Discovery Test Prototype Test Optimization Training Dataset (Alpha-like) Confirmatory Dataset (Beta-like) Validation Dataset (Clinical Trial) Breast CA Signature Test Clinical Samples and Refine Tests Internal Testing Cutoffs Established, Test Refinement Final Preparation for Clinical Trials 39
40 Oncology Test Development In Practice: Breast CA Stratifier Biomarker Discovery Test Prototype Test Optimization Training Dataset (Alpha-like) Confirmatory Dataset (Beta-like) Validation Dataset (Clinical Trial) Breast CA Signature In public domain Breast CA Stratifier 40
41 Oncology Test Development In Practice: Breast CA Monitor Biomarker Discovery Test Prototype Test Optimization Training Dataset (Alpha-like) Confirmatory Dataset (Beta-like) Validation Dataset (Clinical Trial) Breast CA Signature In public domain Breast CA Stratifier Breast CA Monitor 41
42 Why Collaborate with Cepheid? Collaboration Biomarkers Samples for Training & Validation Scientific & Clinical Expertise Lab R&D Expertise KOL Support Post Launch Credibility Cepheid Commercialization of Discoveries World Class Technology Capability Largest Installed Base & Global Reach Test Development Expertise Clinical/Regulatory Expertise Funding 42
43 Oncology Pipeline at Cepheid GeneXpert adding new capabilities Focus monitoring and early detection, the big markets. Leveraging relationships with world-class collaborators Biomarker discovery First announcement of the Johns Hopkins collaboration Sample access First announcement of the ABCSG collaboration Unlocking the clinical potential of DNA methylation detection Able to do that using ctdna as a substrate 43
44 Warren Kocmond Executive Vice President, Chief Operating Officer Joined Cepheid in May 2013 Formerly Lam Research, Verigy, Affymetrix, Applied Materials, Silicon Graphics BS Mechanical Engineering, MS Systems Management 44
45 Foundational Technologies for Cepheid Oncology Paraffin Embedded Tissue Honeycomb ctdna Methylation 45
46 Foundational Technologies for Cepheid Oncology Honeycomb 46
47 Honeycomb: Strategic Extension into High-Level Multiplexing Over 1,000 wells for Real-Time PCR of 100s of Targets Both qualitative and multiplexed quantitative mrna expression Identical Cartridge proven sample prep 47
48 Honeycomb Technical Checklist Hardware Optics Tube Development Run PCR Well Contamination and Control System Available to R&D Volume Manufacturing 48
49 Precise, Real-Time Optics Hardware Optics 49
50 Honeycomb Tube Hardware Optics Tube Development Injection-molded High-volume, low cost manufacturing All tooling design and molding in-house 50
51 PCR Accomplished in Microwells Routinely imaging two-color, 1,000+ wells Hardware Optics Tube Development Run PCR Primers/probes customized in each well Full system prototypes available 51
52 Uniform, Consistent Well-Filling 1 Hardware Optics Tube Development Run PCR DIR Testing Well & Contamination Control 2 3 Q315 52
53 System on Track for Delivery to R&D by End 2015 Hardware Optics Tube Development Run PCR DIR Well Testing & Contamination Control System Available to R&D Q315 End
54 Manufacturing Leverages Semi-Conductor Automation End-to-End Instrument Hardware Optics Image Acquisition Tube Development Run PCR Well & Contamination Control System Available to R&D Volume Manufacturing Q315 End H16 54
55 First Honeycomb Test: Xpert Breast CA Signature Up to 17 mrna targets + 4 controls Replicated 5 times to increase robustness Targeted ex-us in , US in Enabling broadly disseminated testing 55
56 John Bishop Chairman and CEO 56
57 Moving Precision Medicine Closer to the Patient US-IVD BCR-ABL Ultra Breast CA Stratifier Bladder CA Symptomatic Bladder CA Recurrence Breast CA Signature Breast CA Monitor Breast CA Resistance Monitor Pancreatic CA Early Detection CLL Monitor CE-IVD BCR-ABL Ultra Breast CA Stratifier Bladder CA Symptomatic Bladder CA Recurrence Breast CA Monitor CLL Monitor Breast CA Signature Breast CA Resistance Monitor Pancreatic CA Early Detection Pancreatic CA Monitor 57
58 Cepheid s Oncology Opportunity Grows to $2.8B in 2020 $3,000 $2.8B $2,500 $2,000 $1,500 $1,000 $1.2B Pancreatic Leukemia Breast Bladder $500 $0.5B $ Source: Cepheid Estimate
59 Oncology Takeaways: Cepheid is a Credible Competitor + + Targets (Collaborators) Outcomes Data Samples (Collaborators) Delivery System (GeneXpert) 59
60 60 Question & Answers
61 61 Break Time
62 2017 & Beyond Next Phase Innovative Growth Drivers Analyst Event July 27,
63 Introduction Oncology Target Business Model Updated 5 Year Menu Point-of-Care 63
64 Ilan Daskal Executive Vice President & Chief Financial Officer Joined Cepheid in April 2015 Formerly at International Rectifier (acquired by Infineon), Savan Director of Ixia, Audit Committee Chair 64
65 2017 Target Non-GAAP Commercial Business Model As Presented at Cepheid Analyst Event 2012 Gross Margin High 60s R&D 15%-16% S&M ~18% G&A 8% Operating Margin Mid 20s 65
66 2017 Target Commercial Revenue Framework CAGR (Implied) Status Total Commercial CAGR High Teens to 20% 16% High Teens to 20% On Track Commercial Clinical CAGR Low 20%s 20% Low 20%s On Track 66
67 Bridge to Non-GAAP Commercial Gross Margin Target 68% Royalties 67% 66% 65% Mix & Allowance for ASP Erosion 64% 63% 62% 61% Operational Efficiencies 60% 67 59%
68 Non-GAAP Commercial R&D On Track for 2017 Target 25% 20% # Major Trials Peaks in % % 5% 68 0%
69 Non-GAAP Commercial R&D On Track for 2017 Target 25% 20% HPV Investment Peaks in % 10% HPV $5mn HPV $19mn HPV $3mn Test 5% 69 0%
70 Non-GAAP Commercial R&D On Track for 2017 Target 25% 20% HIV HCV HPV HPV Bladder Breast Clinical Trial Investment Eases from 2017 Peaks at 8% of Revenue in % 10% HPV Breast CW Test Normalizes ~3-4% in 2017 Virology Trials ~$10 million HPV Trial $35 $40 million 5% 70 0%
71 Non-GAAP Commercial Sales & Marketing 25% 20% 15% 10% Test Target was ~18% in 2017 Now Expected to be ~20% in 2017 Incremental +150bps Investment in Oncology $3bn Opportunity Incremental +50bps Investment in POC $1.4bn Opportunity 5% 71 0%
72 Non-GAAP Commercial General & Administrative 10% On track for targeted 8% in 2017 Scale Lower Legal Expenses 5% 72 0%
73 2017 Target Non-GAAP Commercial Business Model Commercial Gross Margin High 60s% R&D ~16% S&M ~20% G&A ~8% Operating Margin Mid 20s% 73
74 2017 Target Non-GAAP Emerging Markets Model Commercial Emerging Markets Gross Margin High 60s% High Teens% R&D ~16% S&M ~20% ~4% G&A ~8% Operating Margin Mid 20s% ~14% 74
75 2017 Target Non-GAAP Consolidated Business Model Corporate Commercial Emerging Markets Gross Margin ~60% High 60s% High Teens% R&D ~14% ~16% S&M ~17% ~20% ~4% G&A ~7% ~8% Operating Margin Low 20s% Mid 20s% ~14% 75 Corporate Model assumes ~18% of 2017 revenue is from Emerging Markets.
76 2017 Target Non-GAAP Corporate Business Model Corporate Commercial Emerging Markets Gross Margin ~60% High 60s% High Teens% Continued Focus on Innovation R&D ~14% On a ~16% $ basis, 2017 R&D Investment > 2015 S&M ~17% ~20% ~4% G&A ~7% ~7% Operating Margin Low 20s% Mid 20s% ~14% 76
77 Can Business Model Targets Go Higher? Sustainable Profitability our Near-Term Goal Longer Term Target Business Model to Follow Closer to Achievement of 2017 Targets But 2017 Targets are Not the End Point Higher Margin Tests (e.g. Oncology) More High Volume Tests (e.g. POC) 77
78 Business Model Takeaways On Track to Achieve 2017 Commercial Business Model Targets Corporate Level Targets Added to Target Business Model R&D on $ Basis Continues Aggressively Beyond
79 David H. Persing, M.D, Ph.D. Executive Vice President, Chief Medical & Technology Officer Joined Cepheid in 2005, Director since 2004 Formerly Corixa (acquired by GSK), Mayo Clinic 270 Peer-Reviewed Articles, 5 Text Books MD, PhD (Genetics) 79
80 Investment in Innovative Xpert Test Menu Continues HAI Available Now 17 Tests US, 23 Tests ex-us MRSA Surveillance SA Nasal Complete C. diff (US only) C. diff/epi Norovirus vana for VRE (US only) vana/b for VRE (CE-IVD only) MRSA/SA SSTI MRSA/SA BC Carba-R (CE-IVD only) United States Carba-R Group A Strep Trichomonas HIV Viral Load Breast CA Stratifier BCR-ABL Ultra Pertussis HPV GBS Ultra HCV Viral Load HBV Viral Load CMV Viral Load Bladder CA Monitor Bladder CA Symptomatic GI Panel Meningitis/Encephalitis Vaginitis/Vaginosis CLL Monitor Pancreatic CA Early Detect Breast CA Monitor Breast CA Resistance Monitor Breast CA Signature CID MTB/RIF EV Flu Flu A/B/RSV Ebola (EUA/WHO) Women s/ Sexual Health Virology Oncology/ Genetics CT (CE-IVD only) CT/NG Trichomonas (CE-IVD only) GBS & GBS Lim Broth (US only) HPV (CE-IVD only) HIV Qualitative (CE-IVD only) HIV Viral Load (CE-IVD only) HCV Viral Load (CE-IVD only) BCR-ABL Monitor (CE-IVD only) FII & FV CE-IVD MTB/RIF Ultra Group A Strep HBV Viral Load BCR-ABL Ultra Bladder CA Breast CA Stratifier 28 Pertussis MTB XDR GI Panel Sepsis Panel Vaginitis/Vaginosis GBS Ultra CMV Viral Load Breast CA Signature CLL Monitor Breast CA Monitor Meningitis/Encephalitis Pancreatic CA Early Detect Pancreatic CA Monitor Breast CA Resistance Monitor
81 Investment in Innovative Xpert Test Menu Continues HAI Available Now 17 Tests US, 23 Tests ex-us MRSA Surveillance SA Nasal Complete C. diff (US only) C. diff/epi Norovirus vana for VRE (US only) vana/b for VRE (CE-IVD only) MRSA/SA SSTI MRSA/SA BC Carba-R (CE-IVD only) United States Carba-R Group A Strep Trichomonas HIV Viral Load Breast CA Stratifier BCR-ABL Ultra Pertussis HPV GBS Ultra HCV Viral Load HBV Viral Load CMV Viral Load Bladder CA Monitor Bladder CA Symptomatic GI Panel Meningitis/Encephalitis Vaginitis/Vaginosis CLL Monitor Pancreatic CA Early Detect Breast CA Monitor Breast CA Resistance Monitor Breast CA Signature CID MTB/RIF EV Flu Flu A/B/RSV Ebola (EUA/WHO) Women s/ Sexual Health Virology Oncology/ Genetics CT (CE-IVD only) CT/NG Trichomonas (CE-IVD only) GBS & GBS Lim Broth (US only) HPV (CE-IVD only) HIV Qualitative (CE-IVD only) HIV Viral Load (CE-IVD only) HCV Viral Load (CE-IVD only) BCR-ABL Monitor (CE-IVD only) FII & FV CE-IVD MTB/RIF Ultra Group A Strep HBV Viral Load BCR-ABL Ultra Bladder CA Breast CA Stratifier 28 Pertussis MTB XDR GI Panel Sepsis Panel Vaginitis/Vaginosis GBS Ultra CMV Viral Load Breast CA Signature CLL Monitor Breast CA Monitor Meningitis/Encephalitis Pancreatic CA Early Detect Pancreatic CA Monitor Breast CA Resistance Monitor
82 Extending Lead with Upgrades and Improvements MTB/RIF Ultra BCR-ABL Ultra GBS Ultra 82
83 MTB/Rif Ultra: Targeting Smear & Culture Replacement MTB/RIF Ultra Current test is smear replacement MTB/RIF Ultra could compete with culture High resolution melt: improve accuracy for drug resistance ~30 minutes faster Economic and patient management benefit Targeted ex-us in early
84 Xpert BCR/ABL* Ultra: Moving Toward Test-of-Cure BCR/ABL Ultra Ultrasensitive detection Nested, quantitative amplification Accurate and reproducible measurement of a 4.5 log reduction WHO standardization for each lot Large sample volume input (200 μl to 4 ml) 1st US-IVD oncology product targeted for *Xpert BCR/ABL is currently available ex-us only.
85 Xpert GBS Ultra: Ready to Take GBS Testing to POC GBS Ultra Xpert GBS was our first IVD We ve learned a lot since then Potential for near-patient testing in OB setting Xpress test using fast PCR design rules Improved sensitivity => more intrapartum testing Incorporating Big Tube technology 85
86 86 Xpert GBS Ultra: Ready to Take GBS Testing to POC
87 Opportunity Further Expanded by Claim Extensions Carba-R CT/NG Virology 87
88 Xpert Carba-R*: Test for Carbapenem Resistance Carba-R 51 minute test for gram negative superbugs Detects 91 different resistance genes in 5 gene families Swab specimens for surveillance Claim extensions to include: Isolated colonies (drug resistance) GNR blood cultures Respiratory, urine samples (direct) 88 *Xpert Carba-R is currently available ex-us only.
89 Xpert HCV VL & HIV VL: Plasma to Whole Blood HIV Viral Load Plasma-based test requires centrifuge Claim extension to test from finger-stick Diagnosis and monitoring To enable and further disseminate testing at true point of care 89
90 Xpert CT/NG for Throat, Rectal Samples CT/NG Increasing prevalence of throat & rectal infections Current test limitations are failing to identify as many as 1/2 to 2/3 of cases in high risk groups Claim extension to include throat and rectal swabs targeted for Accelerate decentralization of testing to true point of care 90
91 Menu Takeaways: Continued Leadership in MDx Innovation Cepheid Continues to Innovate with Broad Menu Expansion Program Ongoing Investments Improve Existing Xpert Tests and Extend Lead Claim Extensions Leverage Previous Investments & Expand Opportunities 91
92 John Bishop Chairman and CEO 92
93 Cepheid s Initial Focus in the US was the Hospital Market Independent Reference Lab System Placement Opportunities Hospital Moderate & High Complexity 5,400 POL Moderate Complexity POC CLIA-Waived 93 Source: American Hospital Association, American Hospital Directory, CMS, Cepheid Internal
94 Extending Reach into High Volume Reference Laboratories System Placement Opportunities Independent Reference Lab 200 Hospital Moderate/ High Complexity 5,400 POL Moderately Complex POC CLIA-Waived 94 Source: American Hospital Association, American Hospital Directory, CMS, Cepheid Internal
95 Largest Placement Opportunity is in POL/POC System Placement Opportunities Independent Reference Lab 200 Hospital Moderate/ High Complexity 5,400 POL Moderately Complex 10,000 POC CLIA-Waived 100, Source: American Hospital Association, American Hospital Directory, CMS, Cepheid Internal
96 MDx Test Volume Distribution Today US MDx Test Volume (%), 2015 Independent Reference Lab 38% Hospital Moderate/ High Complexity 59% POL Moderately Complex POC CLIA-Waived <1% 2% 96 Source: Cepheid Estimate
97 Significant Volume Shift to POC US MDx Test Volume (%), 2020 Independent Reference Lab 24% Hospital Moderate/ High Complexity 37% POL Moderately Complex 3% POC CLIA-Waived 35% 97 Source: Cepheid Estimate
98 POC Success Factors Accuracy Time-To-Result Low Cost 98
99 POC Molecular Participants Alere i Roche LIAT GeneXpert 99
100 The POC Trade-Off Performance Time-to-Result 100
101 The POC Trade-Off Performance Time-to-Result 101
102 Introducing: Xpress Family of Products Group A Strep result in <15 minutes Same cartridge optimized for speed Initial Xpress tests targeted in late 2016 Group A Strep & Flu/RSV Xpress tests target time to result <30 minutes 102
103 POC Molecular Participants Alere i Roche LIAT GeneXpert 103
104 A Cepheid POC Option that Delivers it All? + + Accuracy Time-To-Result Low Cost 104
105 A Cepheid POC Option that Delivers it All? Yes! + + Accuracy Time-To-Result Low Cost 105
106 Introducing the GeneXpert Omni Small and Portable Proven Cartridge Technology Durable Low Power Consumption Automatic Connectivity Solid State Integrated Battery 106
107 POC Molecular Participants Alere i Roche LIAT GeneXpert 107
108 GeneXpert Omni: the Optimal POC Solution Alere i Roche LIAT GeneXpert GeneXpert Omni 108
109 Cepheid Cloud Control for Robust Data Management Real-time communications Automated remote data collection Accelerates clinical decisionmaking and patient management System-wide data surveillance 109
110 GeneXpert Omni Available in 2016 Price $2,
111 GeneXpert Omni: the True Point of Care System Game-Changing MDx System for POC Next Generation Connectivity & User Interface Cost Effective Solution Enabling Global Access 111
112 Peter Farrell Executive Vice President, Worldwide Commercial Operations Joined Cepheid in 2014 Formerly Divisional Vice President and General Manager of Abbott Point of Care 112
113 GeneXpert Omni: A Global Opportunity 100,000 US 100,000+ Emerging Markets Emerging Markets CLIA Waived Other POC 113 Source: Cepheid estimate
114 Potential to Transform Use of MDx: the NHLS Example Systems in 224 of 227 Hospitals in South Africa 10 National/Central Hospitals 17 Tertiary Hospitals 48 Regional Hospitals 149 District Hospitals Omni Potential 4,302 Health Centers 114 Source: NHLS & FIND. Used with permission.
115 Emerging Markets: Success Factors to Impact Patient Care Ability to drive decentralization Battery operated Portability, durability Broad test menu System & test cost Quality & speed of result Connectivity & Data Management 115
116 Emerging Markets: GeneXpert Omni Delivers System Price Portability Durability Battery Operated Data Management System Availability GeneXpert Omni $2, lbs 1H16 GeneXpert IV Now $17, lbs Alere q Now ~$15, lbs (w/o battery) Roche LIAT (IQuum) 2016 ~$12, lbs 116
117 GeneXpert Omni: Emerging Markets Menu Xpert MTB/RIF Ultra Xpert HIV Qualitative Xpert HIV Viral Load Xpert HCV Viral Load Xpert Ebola Xpert HPV Xpert CT/NG Full Xpert Menu 117
118 GeneXpert Omni: Global Opportunities 100,000 US 100,000+ Emerging Markets Emerging Markets CLIA Waived Other POC 118 Source: Cepheid estimate
119 Largest Placement Opportunity is in POL/POC System Placement Opportunities Independent Reference Lab 200 Hospital Moderate/ High Complexity 5,400 POL Moderately Complex 10,000 POC CLIA-Waived 100, Source: American Hospital Association, American Hospital Directory, CMS, Cepheid Internal
120 POC: Success Factors for CLIA-Waived Accounts Impact on patient care Return on investment Broad test menu Quality of result Patient satisfaction Time to result Connectivity & Data Management 120
121 POC: GeneXpert Omni is the Answer System Price Portability Time to Result Menu Data Management System Availability GeneXpert Omni ~$2, lbs mins Flu A/B/RSV Strep A (At Launch) Late 2016 GeneXpert I $27,000 9 lbs mins 17 Tests (US) Now Alere i Flu A/B Strep A Now ~$5, lbs ~15 mins Roche LIAT (IQuum) Strep A Now 121 ~$12, lbs ~15 mins
122 US CLIA-Waived Point-of-Care Menu Flu/RSV Xpress Group A Strep Xpress Flu/RSV HPV Xpress Pertussis Xpress GBS Ultra Xpress CT/NG Xpress Vaginitis/Vaginosis 122 Note: Xpress tests have a 15 to 30 minute targeted run-time
123 Cepheid s POC Opportunity Grows to $1.4B in 2020 $1,400 $1,200 $1,000 $800 $600 $400 CT/NG Vaginitis Pertussis HPV Group A Strep Flu/RSV $200 $
124 Distributors to Partner with Direct Cepheid Sales Immediate Access Cost Effective Scalable 124 Distributor 1 Distributor 1 Sales Reps Distribution footprint is for illustrative purposes only and will depend on final distribution agreements.
125 GeneXpert Omni Positively Impacts Patient Care Enables Global Access to Best-in-Class MDx Substantially Expands Addressable Market Hybrid Distribution Accelerates Realization of US POC Opportunity 125
126 John Bishop Chairman and CEO 126
127 Final Thoughts Clear Vision and Ability to Execute on Development of Oncology Franchise. Committed and On Track to Achieve 2017 Target Business Model. Target Menu Demonstrates Ongoing Innovation. Additional Investment in Existing Tests to Extend Lead, Expand Opportunities GeneXpert Omni is the True Point of Care System. 127
128 128 Question & Answers
129 129
130 Thank You. Visit us at Come Visit our Booth #
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016 1 Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking
More informationJefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular
More informationInvesting in Innovation. John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014
Investing in Innovation John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014 1 Cepheid Cepheid Forward-Looking Statement During the course of this presentation, we may make projections
More informationCepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012
Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements
More informationUnified Xpert MTB/RIF Forecasting Initiative
Photo: Riccardo Venturi Unified Xpert MTB/RIF Forecasting Initiative Wayne van Gemert WHO Global TB Programme, Geneva WHO ANNUAL MEETING WITH HIV DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS 11 March 2016
More informationCepheid: Delivering a Better Way
Cepheid: Delivering a Better Way Dieneke Brockmans March 14, 2017 1 Cepheid Our Mission Delivering a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere.
More informationCepheid Update POC QA. Gwynn Stevens, PhD Director Virology Programme HBDC
Cepheid Update POC QA Gwynn Stevens, PhD Director Virology Programme HBDC What will be covered? Quick intro to Cepheid Identification of the need Recognition of the challenges Technology as part of the
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationGeneXpert System. On-Demand Molecular Testing for the Physician Office Laboratory
On-Demand Molecular Testing for the Physician Office Laboratory GeneXpert System How can on-site testing positively impact patient care and clinic operations? A better way. On-site molecular diagnostics
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationDiagnostics: Bench to Bedside Pathway
Diagnostics: Bench to Bedside Pathway Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine www.idx-dx.org The
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationInfectious Disease Diagnostics
Infectious Disease Diagnostics Tackling Infectious Diseases Uppsala Health Summit - October10 th, 2017 Stephan Jäger, Roche Diagnostics GmbH When to tackle infectious diseases Prevention & action contribution
More informationInnovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
More informationMolecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research
Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationLiquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System
Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System Erwin Sablon, Head of R&D, Biocartis NV World CDx, Boston, September 10 th 2015 0 About Biocartis Innovative molecular
More informationEconomic Value Lab Efficiencies Safety Clinical Outcomes. Visit BD Booth AACC/ASCLS 2009 Annual Meeting
Economic Value Lab Efficiencies Safety Clinical Outcomes Visit BD Booth 1225 AACC/ASCLS 2009 Annual Meeting BD Events & Co-Promotions Join us this year at booth #1225 to discover the full spectrum of solutions
More informationPoint-of-Care Molecular Testing
Point-of-Care Molecular Testing Waived Testing April 28, 2016 Raymond P. Podzorski, Ph.D., D(ABMM) Ph.D. Microbiologist St. Mary s Hospital Laboratory Wisconsin Region SSMHC Madison, WI 608-258-6393 raymond_podzorski@ssmhc.com
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationMenu and flexibility with the QIAscreen HPV PCR Test
Menu and flexibility with the QIAscreen HPV PCR Test Sample to Insight HPV and Cervical cancer Worldwide, HPV is one of the most common STIs Persistent infection with high-risk HPV types is linked to virtually
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationRadiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions
Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment
More informationContinuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment
Continuing the momentum to deliver improved performance Robert Cascella Chief Business Leader Diagnosis & Treatment Key takeaways Diagnosis & Treatment strategy is aligned with the Quadruple Aim Gaining
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes 1 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationPOSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH
POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY Integrated Laboratory Network
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationFood & Beverages Food for a growing world
Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More informationGlobal Hepatitis B and C Diagnostics Market
Global Hepatitis B and C Diagnostics Market 2016-2020 Global Hepatitis B and C Diagnostics Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationSEXUAL HEALTH LAB PRODUCTS
SEXUAL HEALTH LAB PRODUCTS Quick, reliable results for in-office testing Start treatments sooner. Enhance patient outcomes. Long waits for results. Delayed diagnosis and treatment. Cancelled follow-up
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationElekta Synergy Digital accelerator for advanced IGRT
Elekta Synergy Digital accelerator for advanced IGRT Setting the standard for confident care The Field of Radiation Therapy is Constantly Changing Being able to take full advantage of the latest clinical
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationSiemens Healthcare Diagnostics
Siemens Healthcare Diagnostics A Global Industry Leader 3.7bn in sales More than 14,500 employees Serving 30,000 customers in more than 120 countries Approximately 244,000 instruments installed R&D spending
More informationBank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008
Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationThe Application of molecular POCT for Influenza and Group A Strep Detection
The Application of molecular POCT for Influenza and Group A Strep Detection Gregory J. Berry, Ph.D., D(ABMM) Assistant Professor, Pathology and Laboratory Medicine Zucker School of Medicine at Hofstra/Northwell
More informationReliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System
Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs The BD ProbeTec ET System The demand is there. The system is here. Now your lab can run up to 15,000 samples a year reliably
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationImaging Systems. Gene Saragnese EVP and GM Imaging Systems
Imaging Systems Gene Saragnese EVP and GM Imaging Systems 1 Imaging Systems Strategy Drive Customer & Patient Experience Quality, reliability and service delivery Ease of use, speed, comfort, dose Deliver
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More information2015 Investor Conference
2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global
More informationMARCH 2017 RESEARCH REPORT
1 MARCH 2017 RESEARCH REPORT LIQUID BIOPSY MARKETS by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides Liquid Biopsy
More informationUN Panel Discussion Millennium Development Goals. Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010
UN Panel Discussion Millennium Development Goals Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010 1 A role for everyone. North Large branded companies Strong engine of innovation Almost
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationTransforming Oncology With Precision Medicine Solutions. Company Overview January 2017
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationGeneXpert HIV-1 Quantitative assay Natasha Samsunder
GeneXpert HIV-1 Quantitative assay Natasha Samsunder CAPRISA INTRODUCTION Cepheid HIV-1 Quant Assay is an automated single cartridge-based quantitative nucleic acid amplification test that is designed
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationMass Spectrometry Made Simple for Clinical Diagnostic Labs
Mass Spectrometry Made Simple for Clinical Diagnostic Labs The SCIEX Topaz System with FDA-Cleared Topaz Vitamin D 200M Assay Kit Mass Spectrometry Made Simple SCIEX Topaz System for Clinical Diagnostics
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationAMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS
AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS Take Control, Molecular Control. 02 04 05 06 06 07 08 08 AMPLIRUN TOTAL RESPIRATORY INFECTIONS TUBERCULOSIS INFECTIONS GASTROINTESTINAL
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationQiagen NV (QIA) - Product Pipeline Analysis, 2017 Update
Qiagen NV (QIA) - Product Pipeline Analysis, 2017 Update Qiagen NV (QIA) - Product Pipeline Analysis, 2017 Update Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationPublic-Private Partnerships: Limelight on Diabetes. Renuka Gadde VP, Global Health October 18, 2012
Public-Private Partnerships: Limelight on Diabetes Renuka Gadde VP, Global Health October 18, 2012 About BD (Becton, Dickinson and Company) Medical technology company $7.5B 29,000 employees Four Areas
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationTitle. subtitle INTERIM RESULTS. Six months ended 30 th June Julian Baines, Group Chief Executive Officer Paul Foulger, Interim Finance Director
Title subtitle INTERIM RESULTS Six months ended 30 th June 2013 Julian Baines, Group Chief Executive Officer Paul Foulger, Interim Finance Director 16 th September 2013 EKF Diagnostics Holdings plc A global
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAfrican Society for Laboratory Medicine
African Society for Laboratory Medicine Strategic Planning for Scaling Up HIV Diagnostics for 90/90/90 WHO/UNAIDS MEETING WITH DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS March 10-11, 2016 Planning and Forecasts
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More information